...Thank you, Mikee, and welcome to all of you who are joining Dr. Shai Gozani and myself for today's Q2 2023 update. By way of background, we are a commercial-stage medical device company addressing unmet needs in chronic pain and in diabetes. Our products are noninvasive. They have no direct competition and offer a worldwide opportunity. Our business is based on a razor-razor blade model, with aftermarket revenue as the primary financial objective. Our principal technologies are Quell, a wearable neuromodulation platform that has transitioned from over-the-counter to prescription, and DPNCheck, a legacy screening technology for peripheral neuropathy, particularly diabetes-related neuropathy. We maintain a strong balance sheet with about $19.6 million in liquid assets. Those are cash and securities. Our capital structure is simple and debt-free. There are approximately 8.6 million common shares outstanding. Today, we reported Q2 revenue of $1.7 million compared with $2.1 million in Q2 of...
